INmune Bio (INMB) Stock Price, News & Analysis

INmune Bio Inc. (NASDAQ: INMB) is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The company describes itself as an inflammation and immunology business, with product platforms designed to address diseases driven by chronic inflammation and cancer by modulating innate immune dysfunction.

According to company disclosures, INmune Bio organizes its pipeline around three main product platforms. The Dominant-Negative Tumor Necrosis Factor (DN‑TNF) platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor (sTNF), a key driver of innate immune dysfunction and a mechanistic driver of many diseases. Product candidates from this platform, branded as XPro™ or XPro1595 (also referred to as pegipanermin), are in clinical development for neurological diseases driven by chronic inflammation, including early Alzheimer’s disease with evidence of neuroinflammation and other indications described in company communications.

The second major platform is CORDStrom™, a patent-pending cell medicine platform comprising aseptic, allogeneic, pooled human umbilical cord‑derived mesenchymal stromal cells (hucMSCs) in suspension for injection or infusion. INmune Bio states that the CORDStrom™ platform leverages proprietary screening, pooling and expansion techniques to create off‑the‑shelf, allogeneic pooled hucMSCs as medicines to treat complex inflammatory, degenerative and autoimmune diseases. CORDStrom™ products are described as high‑quality, off‑the‑shelf, batch‑to‑batch consistent, scalable, cGMP‑manufactured cellular medicines that can be produced with repeatable specifications independent of donor characteristics. The company reports that CORDStrom™ has completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa (RDEB) and is being advanced toward regulatory filings, including a planned Marketing Authorization Application (MAA) in the United Kingdom and a Biologics License Application (BLA) in the United States for RDEB.

INmune Bio’s third platform is INKmune®, described as a pharmaceutical‑grade, replication‑incompetent human tumor cell line that conjugates to resting natural killer (NK) cells. The company reports that INKmune® delivers multiple priming signals to convert a cancer patient’s resting NK cells into tumor‑killing memory‑like NK cells (mlNK cells). In clinical experience disclosed by the company, INKmune®‑primed tumor‑killing NK cells have persisted for more than 100 days in patients. INKmune® is being evaluated in an open‑label Phase I/II trial in men with metastatic castration‑resistant prostate cancer (mCRPC), referred to as the CaRe PC trial, where the company has reported that the trial met its primary and certain secondary endpoints and has been closed to further enrollment.

Within its DN‑TNF platform, INmune Bio emphasizes XPro™ as a selective soluble TNF neutralizer that preserves trans‑membrane TNF (tmTNF) and TNF‑receptor signaling. By selectively neutralizing sTNF, XPro™ is intended to restore healthier innate immune function without the immunosuppressive liabilities associated with traditional non‑selective TNF inhibitors, according to company descriptions. The company has highlighted Phase 2 MINDFuL trial data in early Alzheimer’s disease patients with inflammatory biomarkers, including analyses in a biomarker‑defined subgroup (referred to as the ADi population) and neuroimaging results using advanced MRI‑based measures of cortical microstructure. INmune Bio has also reported that XPro™ is being studied in other neurologic and psychiatric indications in its communications and has discussed plans for regulatory interactions such as an end‑of‑Phase 2 meeting.

The CORDStrom™ platform is positioned by INmune Bio as a systemic cell therapy approach for RDEB and potentially other debilitating conditions. Company materials describe CORDStrom™ as an off‑the‑shelf, allogeneic umbilical cord tissue‑derived mesenchymal stromal cell therapy that has shown promising results in a blinded randomized Phase 2 trial in RDEB, including reported improvements in measures such as itch, pain, wound scores and quality of life, as summarized in company news. INmune Bio has also reported the successful completion of pilot‑scale commercial manufacturing runs of CORDStrom™ at a cell and gene therapy manufacturing center in the United Kingdom, which the company views as an important step toward large‑scale, commercial‑ready production and future regulatory submissions.

For INKmune®, INmune Bio describes the therapy as a patient‑friendly NK cell–priming treatment delivered by simple intravenous infusion in an outpatient setting. The company states that INKmune® does not require pre‑medication, conditioning, or additional cytokine therapy, and that it is tumor‑agnostic, with potential application to multiple NK‑resistant tumor types. In the CaRe PC trial in metastatic castration‑resistant prostate cancer, INmune Bio has reported that INKmune™ was well tolerated at all three dose levels and that patients with low NK cell activation at baseline showed the greatest improvements in NK cell activation biomarkers, helping to define a target population for future trials.

INmune Bio is incorporated in Nevada and lists its principal executive offices in Boca Raton, Florida in SEC filings. Its common stock, with a par value of $0.001 per share, trades on The Nasdaq Stock Market LLC under the symbol INMB. As a clinical‑stage company, INmune Bio reports that its product candidates, including CORDStrom™, XPro1595 (XPro™, pegipanermin) and INKmune®, have not been approved by the U.S. Food and Drug Administration or other regulatory authorities, and that there can be no assurance that they will be approved or achieve specific clinical outcomes.

INmune Bio’s public communications and SEC filings also highlight its use of a precision medicine approach across its platforms, focusing on biologically defined patient subgroups such as individuals with Alzheimer’s disease and high inflammatory burden or cancer patients with specific NK cell functional profiles. The company emphasizes that its programs are in various stages of clinical development and that it is engaged in ongoing research, regulatory interactions, and manufacturing scale‑up activities to advance its pipeline.